Objectives To evaluate the safety, tolerance, and efficacy of palivizumab in children with hemodynamically significant congenital heart disease (CHD).
L
ower respiratory tract disease caused by respiratory syncytial virus (RSV) accounts for more than 125,000 pediatric hospitalizations and approximately 6.3 deaths per 100,000 person-years among children up to 4 years of age in the United States. [1] [2] [3] Children more likely to have increased morbidity and mortality rates as the result of complications of RSV infection include those with prematurity, chronic lung disease, or congenital heart disease (CHD). 4, 5 In children with cardiac abnormalities, one early study showed a 37% fatality rate for RSV-infected, hospitalized infants with CHD. 6 More recent studies suggest that among infants with CHD who are hospitalized with RSV disease, 33% will require treatment in a pediatric intensive care unit (ICU), and 2.5% to 3.4% die of complications of the RSV infection. 7, 8 Infants with pulmonary hypertension are at greatest risk from RSV infection. 6, 7 In addition, nosocomial RSV infection has a particularly adverse impact on infants and children who become infected in the immediate preoperative or postoperative period for heart surgery. 9, 10 Two early efficacy trials with a hyperimmune RSV globulin (RSV-IGIV) to prevent RSV infection included infants and children with CHD. As part of the initial National Institutes of Health-sponsored RSV-IGIV trial, 87 infants with CHD were enrolled among 249 high-risk subjects. 11 Results of this trial demonstrated an overall 63% relative reduction in RSV hospitalization compared with the control group; however, the trial was not powered for subgroup analysis of children with heart disease. A second trial conducted in 1992 to 1995 evaluated 416 children #4 years of age with CHD who were assigned to receive monthly RSV-IGIV or to an uninfused control group. 12 Results showed only a trend toward RSV disease prevention. Interpretation of results in the second study was confounded by a disproportionately higher number of children with cyanotic CHD in the treatment group. An unexpected increase in surgically related adverse events in RSV-IGIV recipients with cyanotic CHD occurred relative to the control group. Although the precise explanation for this observation in infants with cyanotic heart disease is unclear, it may have been caused by an alteration in blood viscosity after administration of RSV-IGIV to patients with an elevated hematocrit concentration.
The use of RSV-IGIV for prophylaxis of high-risk infants with prematurity and chronic lung disease has been largely replaced by a humanized murine monoclonal anti-F glycoprotein antibody preparation, palivizumab. 13 Palivizumab has been studied extensively in children with prematurity with or without chronic lung disease and shown to be safe and effective at a dose of 15 mg/kg monthly, reducing the incidence of RSV-associated hospitalizations by 55%.
14 Palivizumab was expected to be safe and effective in infants with cyanotic heart disease because it is administered in a 100-fold lesser volume and 50-fold smaller protein load than RSV-IGIV. Nonetheless, pending the availability of data in CHD patients, palivizumab was recommended for use in children with CHD only if heart disease was hemodynamically insignificant and only if an infant qualified for prophylaxis on the basis of the presence of prematurity or chronic lung disease. 15 The purpose of the current study was to address the safety, tolerance, and efficacy of palivizumab in infants and young children with hemodynamically significant CHD.
METHODS

Design and Patient Population
This was a multicenter, randomized, double-blind, placebo-controlled trial in children with CHD. The study was conducted during 4 consecutive RSV seasons, 1998 through 2002. Each child participated during only one season. The local institutional review board or independent ethics committee approved the study protocol, and parents or guardians gave written informed consent before participation. The study was conducted at 76 centers in the United States (n = 47), Canada (n = 6), Sweden (n = 3), Germany (n = 4), Poland (n = 6), France (n = 4), and the United Kingdom (n = 6).
The primary objective of this study was to compare the safety, tolerance, and efficacy of palivizumab with placebo when given monthly for the reduction of the incidence of RSV hospitalization among children with hemodynamically significant CHD. The secondary objectives were to determine the effect of monthly palivizumab prophylaxis compared with placebo on RSV hospitalization outcomes as measured by total days of RSV hospitalization, total RSV hospital days with increased oxygen requirement, incidence and total days of RSV-associated intensive care, and incidence and total days of RSV-associated mechanical ventilation (total days were summarized per 100 randomized children); to describe the effect of cardiac bypass on serum palivizumab concentrations; and to determine palivizumab trough concentrations before the second and fifth doses.
Children were eligible if they were #24 months old at the time of random assignment, had documented hemodynamically significant CHD determined by the investigator, and had unoperated or partially corrected CHD. Children were not eligible if they had unstable cardiac or respiratory status, including cardiac defects so severe that survival was not expected or for which cardiac transplantation was planned or anticipated; were hospitalized, unless discharge was anticipated within 21 days; anticipated cardiac surgery within 2 weeks of random assignment; required mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure, or other mechanical respiratory or cardiac support; had associated noncardiac anomalies or end-organ dysfunction resulting in anticipated survival of <6 months or unstable abnormalities of end-organ function. Additional exclusion criteria were known HIV infection; acute RSV or other acute infection or illness; previous receipt of palivizumab or other monoclonal antibody; receipt of investigational agents within the previous 3 months (other than investigational agents commonly used during cardiac surgery or the immediate postoperative period, ie, nitric oxide); current participation in other investigational protocols of drugs or biological agents; or receipt of intravenous immune globulin (IGIV), including RSV-IGIV (RespiGam, MedImmune, Inc, Gaithersburg, Md), within 3 months before random assignment or anticipated use of IGIV, RSV-IGIV, or open-label palivizumab during the study period. Children with uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus were excluded.
Random assignment was based on a computer-generated sequence and was stratified by site to reduce the effect of practice discrepancies and anatomic cardiac lesion (cyanotic or ''other''). Random assignment was performed centrally with the use of an interactive voice response system. Children with the following anatomic diagnoses were included in the cyanotic stratum: pulmonary atresia with ventricular septal defect, pulmonary atresia with intact septum, tetralogy of Fallot, single ventricle including hypoplastic left or right heart, tricuspid atresia, double-outlet right ventricle with transposed great arteries, Ebstein anomaly, or D-transposition of the great arteries with/without ventricular septal defect, with/without pulmonary stenosis. The remaining children were stratified to the ''other'' (acyanotic) stratum.
Eligible children were randomly assigned (1:1) to receive either palivizumab (15 mg/kg) or an equal volume of identically appearing placebo (same formulation without antibody and with 0.02% Tween-80 added) by intramuscular injection every 30 days for a total of 5 doses. Palivizumab and placebo were supplied as lyophilized product in coded vials that were reconstituted by the pharmacist with sterile water for injection (final concentration of palivizumab is 100 mg/mL) and dispensed in a syringe that did not identify the contents.
Outcomes
Children were followed for 150 days from random assignment (30 days after the last scheduled study injection) for hospitalization and for the occurrence of adverse events. All hospitalizations were identified, and in children with an acute cardiorespiratory hospitalization, RSV antigen testing of respiratory secretions was performed with the use of commercially available tests. The primary end point of the trial was the incidence of RSV hospitalization, including primary RSV hospitalizations and nosocomial RSV hospitalizations. A primary RSV hospitalization was defined as a hospitalization for an acute cardiorespiratory illness in which the RSV antigen test was positive within 48 hours before or after admission. Deaths occurring outside the hospital that could be demonstrated to be associated with RSV were also considered as primary RSV hospitalization end points. A nosocomial RSV hospitalization was one in which hospitalized patients had an objective measure of worsening cardiorespiratory status reported as a serious adverse event and the RSV antigen test was positive. RSV hospitalizations were monitored for total days, days of supplemental oxygen, days of intensive care, and days of mechanical ventilation. Decisions on hospitalization, discharge, and other aspects of therapy for RSV disease were left to the treating physician's discretion. Any adverse change from a child's medical condition at entry was reported as an adverse event, graded for severity, and assessed by the blinded investigator as to potential relation to study drug. Serious adverse events were those that resulted in death; were lifethreatening; resulted in hospitalization or prolonged hospitalization; resulted in significant disability; or were another important medical event that required intervention to prevent one of the above outcomes.
Serum was collected before the first, second, and fifth injections of study drug, and, if cardiac bypass was used during surgery, before bypass and on the day after bypass. Palivizumab concentrations were analyzed with the use of a previously described enzyme immunosorbent assay. 16 Serum RSV neutralizing antibody titers at study entry were assessed in a plaque reduction neutralization test. 17 
Sample Size and Statistical Analysis
Assuming an RSV hospitalization rate of 12.0% in the placebo group compared with 7.2% in the palivizumab group, approximately 1280 children were to be randomly assigned (1:1) to provide 80% power of showing a 40% relative reduction in the incidence of RSV hospitalizations, using a 2-sided a-level of 0.05. After completion of the second year of the study, the Data Safety Monitoring Board undertook a planned interim analysis of the primary end point of RSV hospitalization. Six hundred ninety-eight patients representing approximately 54% of the total number of patients had completed the study at that time. The Lan-DeMets procedure, using the approximate O'Brien-Fleming boundaries, was used to determine the adjusted P value (.048) required for significance of the primary end point.
All randomly assigned patients were included in the safety and efficacy analyses. Statistical comparison of groups was performed with the Fisher exact test for categorical variables and Wilcoxon rank sum test for continuous variables. The Kaplan-Meier analysis assessing time to first RSV hospitalization was used as a confirmatory test accounting for incomplete follow-up. The Cochran-Mantel-Haenszel test was used to evaluate the primary end point across strata. Logistic regression was performed with the use of predefined variables (age, sex, and stratum). Treatment groups were compared for adverse events (COSTART coded terms) by evaluating the number of children in each group with at least one event by body system and the distribution of severity and relatedness of these events.
Patients who received at least one dose of study drug were included in the analyses of serum palivizumab concentrations, unless they were known to have received off-study palivizumab or had a documented dosing error (eg, received the incorrect study drug on at least one occasion).
RESULTS
Starting on November 1 and ending on or before December 31 of each year between 1998 and 2001, a total of 1287 patients were randomly assigned. Study sites in the United States and Canada randomly assigned 800 (62.2%) and 133 (10.3%) children, respectively. The remaining children were randomly assigned in Poland (150, 11.6%), the United Kingdom (95, 7.4%), Germany (49, 3.8%), Sweden (33, 2.6%), and France (27, 2.1%). From 1 to 45 patients were randomly assigned per site, with an average of 17 patients per site. Six sites randomly assigned less than 5 patients, and 25 sites randomly assigned 20 or more patients.
A total of 1287 children were randomly assigned: 639 to the palivizumab group and 648 to the placebo group. Overall, 93.0% of children in the palivizumab group and 91.8% in the placebo group received all five planned injections; 95.6% in the palivizumab group and 95.5% in the placebo group completed the study.
The groups were balanced for demographic characteristics, RSV risk factors, and parameters of cardiovascular disease (Table I) . Of the 1287 children randomly assigned in the study, 682 (53.0%) were in the cyanotic stratsum and 605 (47.0%) in the ''other'' stratum. The distribution of cardiac lesions was balanced between the two treatment groups. The cyanotic lesions, single ventricle including hypoplastic left or right heart and tetralogy of Fallot, accounted for 21.9% and 11.4%, respectively, of all children enrolled, whereas the acyanotic lesions, ventricular septal defect and atrioventricular septal defect, occurred in 18.0% and 7.2%, respectively, of those enrolled. and 2 palivizumab recipients) had more than one RSV hospitalization.
The result was robust in sensitivity analyses including (1) addition of adjusted rates for those children with respiratory hospitalizations for whom an RSV antigen test was not performed (P = .004), (2) inclusion of children who did not have an RSV hospitalization documented and did not complete follow-up through day 150 (P = .005), and (3) inclusion of children (n = 3) hospitalized with virologic evidence of RSV but who did not meet the protocol defined criteria for RSV hospitalization (P = .002). Cochran-MantelHaenszel analysis of RSV hospitalization across strata was significant (P = .003), and treatment remained significant (P = .004) in logistic regression performed with predefined variables (age, sex, and cardiac strata). Reductions in RSV hospitalization were seen in both strata, although the study was not powered for subgroup analyses. In the cyanotic stratum, RSV hospitalizations were reduced by 29%, from 7.9% in the placebo group to 5.6% in the palivizumab group (P = .285). In the ''other'' stratum, RSV hospitalizations were reduced by 58%, from 11.8% in the placebo group to 5.0% in the palivizumab group (P = .003). Cochran-Mantel-Haenszel analyses of RSV hospitalization across sex, age at entry (#6 months or >6 months), weight at entry (#6 kg or >6 kg), race (white or other), location (United States, Canada, Europe), study year (year 1, 2, 3, 4), and neutralizing antibody at entry (<1:200 or $1:200) all were highly significant (P < .01), indicating consistency of the benefit across these subgroups. RSV hospitalization rates for infants <6 months old were 12.2% placebo versus 6.0% palivizumab, with corresponding rates of 7.3% versus 6.1% for infants 6 to 12 months old and 4.3% versus 1.8% for children 1 to 2 years old. RSV hospitalization rates for the placebo and palivizumab groups, respectively, by locations were the United States (10.6% vs 5.9%), Canada (11.9% vs 7.6%), and Europe (7.0% vs 3.0%).
Secondary Efficacy End Points
As shown in Table III , children randomly assigned to palivizumab had significantly fewer total days of RSV hospitalization per 100 children (56% reduction; 129.0 days placebo vs 57.4 days palivizumab, P = .003) and RSV hospital days with increased oxygen requirement per 100 children (73% reduction; 101.5 days placebo vs 27.9 days palivizumab, P = .014). A similar trend favoring palivizumab was observed for incidence of RSV-associated intensive care (46% reduction, P = .094), days of RSV-associated intensive care per 100 children (78% reduction, P = .080), incidence of RSVassociated mechanical ventilation (41% reduction, P = .282), and days of RSV-associated mechanical ventilation per 100 children (88% reduction, P = .224). Prolonged RSV hospitalization ($14 days) occurred in fewer palivizumab recipients compared with placebo recipients (16 placebo vs 5 palivizumab). yChildren with more than one RSV hospitalization were counted only once. Two children (1 in each treatment group) died in the ER from RSV bronchiolitis and, by convention, were counted as end points. zKaplan-Meier estimate of the proportion with RSV hospitalization at 150 days. Deaths before RSV hospitalization, withdrawals, and lost events were treated as censored. For the 2 children who died in the ER from RSV bronchiolitis, total days on study were used for the analysis. §Events were added to each treatment group in proportion to the number of children who would have had a RSV hospitalization if the proportion hospitalized was equal to that of the other treatment group (n 3 0.097 events added for palivizumab; n 3 0.053 events added for placebo). kProportional adjustments made for the number of children (14 palivizumab; 9 placebo) who had no endpoint and who had a hospitalization for an acute cardiorespiratory illness with evidence of respiratory infection (coryza, fever, apnea), without alternative etiology and with no RSV antigen test done (or negative test and done outside the protocol-specified window). {Proportional adjustments made for the number of children (28 palivizumab; 29 placebo) who stopped follow-up before day 150 and who had no endpoint through the last follow-up visit. **Three children (1 palivizumab, 2 placebo) who were hospitalized with virologic evidence of RSV lower respiratory tract infection but did not meet the protocol-specified case definition were added. An 11.8% reduction in the incidence of hospitalization for any cause was observed in the palivizumab group (62.3% placebo vs 54.9% palivizumab, P = .008). Differences in the relative rates of RSV hospitalization were major contributions to this difference; when RSV hospitalizations were removed from the analysis, the reduction in hospitalization rate was 9.3% (59.0% placebo vs 53.5% palivizumab, P = .056). The proportion of children with a cardiorespiratory hospitalization was 55.4% in the placebo group and 50.2% in the palivizumab group (P = .066).
Safety and Tolerability
As shown in Table IV , the proportion of children with adverse events, adverse events that required medical intervention, and adverse events judged by the blinded investigator to be related to the study drug was similar between the two groups. No child had study drug discontinued for a related adverse event. Few adverse events were reported at an absolute incidence $1% higher in the palivizumab group compared with the placebo group. Those adverse events were limited to fever (27.1% palivizumab vs 23.9% placebo), infection (5.6% vs 2.9%), study drug injection site reaction (3.4% vs 2.2%), URI (47.4% vs 46.1%), conjunctivitis (11.3% vs 9.3%), arrhythmia (3.1% vs 1.7%), and cyanosis (9.1% vs 6.9%). None of the events reported as arrhythmia and one reported as cyanosis (placebo recipient) were judged related to the study drug. The most common injection site reactions were redness, swelling and bruising; none was serious. The incidence of serious adverse events was significantly lower in the palivizumab group compared with the placebo group (55.4% vs 63.1%, P = .005, Table IV ). This trend was observed in both the cyanotic stratum (59.9% vs 67.1%, P = .056) and the ''other'' stratum (50.3% vs 58.7%, P = .041). When serious adverse events reported during all RSV hospitalizations were removed from the analysis, the P value was .043. Arrhythmia was reported as a serious adverse event in 0.2% and 0.3% of the palivizumab and placebo groups, respectively. Cyanosis was reported as a serious adverse event in 3.6% of the palivizumab group (23 patients) and 2.2% of the placebo group (14 patients); these included 20 and 14 patients, respectively, in the cyanotic stratum and 3 and 0, respectively, in the ''other'' stratum. Within 30 days after onset of the cyanotic serious adverse event, equal proportions of the palivizumab group (14 patients, 2.2%) and placebo group (12 patients, 1.9%) had earlier-than-planned or urgent surgery or died (1 in each group). No serious adverse events related to palivizumab were reported. The incidence rates of cardiac surgeries classified as planned, earlier than planned, or urgent were balanced between treatment groups (Table V) . A total of 48 children died during the study: 21 (3.3%) in the palivizumab group and 27 (4.2%) in the placebo group (Table IV) . No deaths were attributed to study drug. Six children (4 cyanotic and 2 ''other'' strata) in the palivizumab group and 5 children (2 cyanotic and 3 ''other'' strata) in the placebo group had surgery-associated deaths. Deaths associated with RSV infection occurred in 2 patients in the palivizumab group and 4 patients in the placebo group. 
Serum Palivizumab Levels
Mean (±SD) serum palivizumab concentrations before the second and fifth doses were 55.5 (±19) lg/mL and 90.8 (±35) lg/mL in the palivizumab group and 0.4 (±5) lg/mL and 0.1 (±2) lg/mL in the placebo group. Only 7.9% of the palivizumab group tested had concentrations before the second dose <30 lg/mL, the concentration found to reduce mean pulmonary RSV titers by 2 log 10 in the cotton rat model. 13 Paired serum was available before and after cardiac bypass for 139 palivizumab recipients. Before and after cardiopulmonary bypass, the mean (±SD) serum palivizumab concentrations were 98.0 (±52) lg/mL and 41.4 (±33) lg/mL, respectively. This represents a reduction of 58% (P = .0001) in serum palivizumab concentration after bypass.
DISCUSSION
This large, placebo-controlled trial demonstrates the benefit of palivizumab prophylaxis in children with CHD. Children receiving prophylaxis had a 45% (95% CI: 23, 67) relative reduction in RSV hospitalization. These results are consistent with the IMpact-RSV trial in children with prematurity with or without chronic lung disease, in which a 55% (95% CI: 38, 72) relative reduction was observed.
14 The reduction in RSV hospitalization rate was evident in both the cyanotic (7.9% placebo vs 5.6% palivizumab, P = .285) and the ''other'' or acyanotic strata (11.8% vs 5.0%, P = .003), although reduction was statistically significant only in the acyanotic stratum. Using the predicted 12.0% placebo RSV hospitalization rate, the power to show a statistically significant reduction of 40% in the cyanotic stratum was 51%. Using the low placebo RSV hospitalization rate of 7.9% observed in the cyanotic stratum, the post hoc power estimation is 34%. When RSV hospitalization was assessed across strata through the use of the Cochran-Mantel-Haenszel method, the P value was .003, consistent with benefit in both strata. This trend was consistent in patients from all geographic areas (United States, Canada, and Europe) and was evident in male and female subjects, in children #6 months and >6 months of age at entry, in children #6 kg and >6 kg at entry, and in children of either white race or all other races combined.
The reduction in RSV hospitalization was accompanied by a significant reduction in days of RSV hospitalization per 100 children randomly assigned (129.0 days placebo vs 57.4 days palivizumab, P = .003) and RSV hospital days with increased oxygen requirement per 100 children (101.5 days vs 27.9 days, P = .014). Prolonged RSV hospitalization ($14 days) occurred in fewer palivizumab recipients compared with placebo recipients (16 placebo vs 5 palivizumab). The incidence and days of RSV-associated intensive care and the incidence and days of RSV-associated mechanical ventilation appeared lower in the palivizumab group; the study was not powered to show statistical significance for these outcomes. Deaths associated with RSV infection occurred in 2 patients in the palivizumab group and 4 patients in the placebo group, a trend similar to that seen in a previous RSV-IGIV study in patients with CHD (1 patient in the RSV-IGIV group and 3 patients in the control group). 12 In the current study, the safety profile of palivizumab in patients with CHD was similar to that observed in other pediatric populations. Children receiving palivizumab prophylaxis had a slightly higher rate of fever (3.2% difference between groups) and reactions at the injection site (1.2% difference) compared with control subjects. These events were generally of low severity and did not result in alteration of the prophylaxis regimen. The incidence of adverse events was similar between groups, whereas there was significantly lower incidence of serious adverse events among palivizumab recipients relative to control subjects. Serious adverse events coding to cyanosis were somewhat more frequent in the palivizumab group (23 children, 3.6%) than the placebo group (14 children, 2.2%). However, cyanotic serious adverse events leading to earlier-than-planned or urgent surgery or death (1 child in each group) were balanced between treatment groups. Rates of earlier-than-planned and urgent cardiac surgeries were carefully and prospectively monitored throughout the course of the study. There were no differences observed in the rates of these events between palivizumab and placebo recipients.
Previous studies suggested a potential problem in RSV-IGIV recipients with regard to deaths associated with surgery. 11, 12 A total of 48 children died during the current study: 21 (3.3%) in the palivizumab group and 27 (4.2%) in the placebo group. Deaths associated with cardiac surgery were similar between treatment groups. No deaths were attributed to study drug. Thus the results from this study demonstrate the safety of monthly palivizumab prophylaxis in children with CHD.
Patients with CHD receiving palivizumab prophylaxis may undergo cardiopulmonary bypass during surgical procedures. Data obtained during this study demonstrate that serum palivizumab concentrations in children undergoing open heart surgery were reduced by >50% after the cardiopulmonary bypass procedure. Because serum concentrations may fall below a protective level, it is appropriate to administer another dose of palivizumab (15 mg/kg) after surgery. The results of this trial demonstrate that palivizumab can be administered safely to infants and young children with hemodynamically significant CHD. Monthly prophylaxis results in a 45% reduction in RSV hospitalization in this high-risk population. Guidelines for the use of palivizumab in patients with CHD have been issued by the American Academy of Pediatrics, 18 Респираторно-синцитиальный вирус (РСВ) являет-ся основным возбудителем тяжелых инфекций нижних дыхательных путей (ИНДП) у детей первых двух лет жиз-ни. Данный РНК-содержащий вирус относится к роду Pneumovirus семейства парамиксовирусов; получил свое название в связи со специфичным цитопатиче-ским эффектом, оказываемым на пораженные клетки. Внешняя липидная оболочка РСВ несет два гликопротеи-да -G-белок, с помощью которого вирус прикрепляется к клетке, и F-белок, облегчающий проникновение вируса в клетку посредством слияния оболочки вируса с клеточ-ной мембраной.
У детей грудного возраста в эпидемический сезон РСВ-инфекцией обусловлено до 74% бронхиолитов и 54% пневмоний, госпитализаций -до 80 и 60%, соответ-ственно [1] . Общий «вклад» РСВ-инфекции в респира-торные заболевания у детей всех возрастов превыша-ет число заболеваний гриппом и его осложнений: так, у детей в возрасте до 1 года отмечена значимо более высокая частота острого бронхиолита в период подъ-ема активности РСВ-инфекции по сравнению с актив-ным периодом гриппа (медиана различия 2,702; 95% доверительный интервал [ДИ] 929-4,867). Это сравне-ние было также значимым у детей в возрасте 1-4 лет (994; 95% ДИ 338-1747). В период подъема активно-сти РСВ-инфекции было зарегистрировано повышение частоты простуды для детей в возрасте до 1 года (3,728; 95% ДИ 632-5,867) и 5-14 лет (339; 95% ДИ 59-768) по сравнению с активным периодом гриппа. Из резуль-татов данного исследования [2] можно сделать вывод, что клиническое бремя заболеваний, связанных с РСВ, гораздо более значимо по сравнению с вирусом гриппа у пациентов всех возрастных групп, обратившихся к вра-чу общей практики (рис. 1).
W. Thompson и соавт. проанализировали данные по смертности из Национального центра статистики здравоохранения США (NCHS) для оценки ежегодной смертности в связи с гриппом и РСВ-инфекцией в зави-симости от возраста [3] . Летальные исходы в связи с гриппом и РСВ параллельно оценивались за сезоны 1990/91-1998/99 гг. Оказалось, что у детей в воз-расте до 1 года РСВ является основной вирусной при-чиной смертельных исходов, превышая уровень смерт-ности от гриппа в 8,8 раз (показатель смертности 5,3 и 0,6 на 100 000 пациенто-лет, соответственно).
В странах с умеренным климатом ежегодный эпи-демический подъем заболеваемости РСВ-инфекцией наблюдается поздней осенью, зимой и ранней весной. В России этот период, как показали результаты проспек-тивного мультицентрового эпидемиологического иссле-дования распространенности РСВ у детей первых двух лет жизни, проведенного в сезон 2008-2009 г., длится с ноя-бря по апрель (рис. 2). В эти месяцы РСВ -основная причина госпитализаций детей с ИНДП. У 197 пациентов (из 519) тест на РСВ был положительным, что состави-ло 37,96% (95% ДИ 33,77; 42,29). Распространенность РСВ-инфекции среди госпитализированных детей в воз-расте р 2 лет сопоставима с аналогичными показате-лями в других развитых странах мира, хотя период пика Рис. 1. Заболеваемость, связанная с РСВ и гриппом, у детей грудного возраста [2] Распространенность РСВ Иммунопрофилактика и иммунотерапия в педиатрии в исследуемом сезоне пришелся на более позднее время (март-апрель), чем было описано ранее [4] . Начальным проявлением РСВ-инфекции у детей грудного возраста обычно является поражение верхних дыхательных путей (ринит, фарингит), продолжающее-ся несколько дней. Затем могут возникнуть проявления ИНДП -бронхиолита и/или пневмонии. Клиническая картина РСВ-бронхиолита складывается из нереспиратор-ных (повышение температуры тела, раздражительность, сонливость, отказ от еды, остановка дыхания централь-ного генеза) и респираторных симптомов. Респираторные симптомы включают внезапно появляющееся свистя-щее дыхание, тахипноэ до 90 в мин, одышку, насморк и кашель, цианоз; рассеянные влажные мелкопузырча-тые и сухие свистящие хрипы, крепитацию и ослабление дыхания при аускультации легких. Общая продолжитель-ность РСВ-бронхиолита обычно составляет 10-14 дней, у новорожденных -до 21 дня [5] . Тяжесть бронхиолита в начале заболевания наиболее точно позволяет оценить степень насыщения крови кислородом (сатурация, SaO 2 ) при дыхании атмосферным воздухом. Сатурация O 2 < 95%, а также PаO 2 < 65 мм рт. ст., PaCO 2 > 40 мм рт. ст., недо-ношенность в анамнезе, ателектаз на рентгенограмме, частота дыхания > 70 в 1 мин, возраст менее 3 мес указы-вают на тяжелое течение бронхиолита и расцениваются в качестве показаний для госпитализации [6] .
К осложнениям РСВ-инфекции относятся гипоксемия, апноэ, дыхательная недостаточность, которые приводят к интубации и искусственной вентиляции легких (ИВЛ). Бактериальная пневмония развивается менее чем у 1% пациентов, потребовавших стационарного лечения; сре-ди бактериальных осложнений бронхиолита чаще реги-стрируется инфекция мочевой системы. Отсроченными осложнениями РСВ-бронхиолитов являются повторные эпизоды свистящего дыхания, отклонения от нормы пока-зателей функции внешнего дыхания (ФВД), гиперреактив-ность дыхательных путей, облитерирующий бронхиолит и бронхиальная астма [5] . Риск развития бронхиальной астмы у детей, обусловленной перенесенной в младен-честве РСВ-инфекцией, нарастает по мере взросления ребенка и составляет до 22,3% в исследованиях, вклю-чавших пациентов младше 5 лет, до 26,6% -в возрасте 5-11 лет и 31,6% -в возрасте 12 лет и старше [7] .
В настоящее время в педиатрии сложилась концепция модифицирующих факторов, оказывающих неблагопри-ятное влияние на течение и исход инфекционных заболе-ваний. Инфекция, вызываемая РСВ, не является в этом отношении исключением. К детям из групп высокого риска по развитию тяжелой РСВ-инфекции нижних дыхательных путей, требующей госпитализации, в том числе в отделе-ние интенсивной терапии, назначения дополнительного кислорода, проведения ИВЛ и способной привести к смер-ти, относятся недоношенные дети с/без бронхолегочной дисплазии (БЛД) и дети с врожденными пороками серд-ца (ВПС) (табл. 1). Подтверждением тяжелого течения РСВ-бронхиолита у недоношенных детей с БЛД служат результаты многоцентрового эпидемиологического иссле-дования в Российской Федерации [15] , а также собствен-ные наблюдения за 9 пациентами, пересшими данную инфекцию в октябре-ноябре 2011 г. [16] .
К другим факторам риска, достоверно повышающим риск тяжелого течения РСВ-инфекции, относятся: мужской пол, рождение в апреле-сентябре, низкий для данного гестационного возраста вес, искусственное вскармлива-ние, воздействие табачного дыма, посещение организо-ванных детских коллективов, перенаселенность жилища, низкий социально-экономический статус семьи, контакт с детьми младшего возраста, врожденный или приобре-тенный иммунодефицит, муковисцидоз, нейромышечные заболевания, синдром Дауна и анатомические дефек-ты, нарушающие нормальный мукоцилиарный клиренс [17] [18] [19] [20] . Развитию тяжелой дыхательной недостаточно-сти у этих детей способствуют недоразвитие дыхательных путей, их меньший диаметр, необратимая бронхиальная обструкция, вязкий бронхиальный секрет, более высокое бронхиальное сопротивление при воспалении, неадек-ватный иммунный ответ, прогрессирующие гемодинами-ческие нарушения (легочная гипертензия) при наличии ВПС, слабость дыхательной мускулатуры [21] .
Терапия РСВ-бронхиолита носит симптоматический характер, а число эффективных с позиций доказатель-ной медицины вмешательств, согласно международным руководствам по лечению детей, страдающих данным заболеванием, Американской академии педиатрии (AAP) и Шотландской межколлегиальной сети обмена рекомен-дациями (SIGN) [22, 23] , немногочисленно (табл. 2).
В настоящее время акцент в ведении младенцев с бронхиолитами смещается в сторону профилактики рас-пространения тяжелых форм РСВ-инфекции в лечебных учреждениях: проводится лабораторное подтверждение инфекции с помощью экспресс-методов, изоляция боль-ных, мытье рук, ношение масок, осмотр посетителей на наличие симптомов респираторной инфекции.
Попытки создать вакцину против РСВ предприни-мались с 1960-х годов. Первоначальные исследования с применением вакцины, содержащей респираторно-синцитиальный вирус, инактивированный формалином, показали, что в группе иммунизированных развивались Таблица 1. Частота госпитализаций, потребности в реанимации и искусственной вентиляции легких (ИВЛ), общая смертность у детей с тяжелым течением РСВ-бронхиолита более тяжелые заболевания, связанные с РСВ, во вре-мя последующей сезонной вспышки этой инфекции [24] . Несмотря на то, что подходы к разработке вакцин с использованием рекомбинантных методов выглядят многообещающими, эффективной и безопасной вакцины против РСВ в настоящее время не существует. На сегодняшний день в профилактике тяжелых форм РСВ-инфекции сделан новый шаг, создан принципиаль-но новый класс препаратов -моноклональные антите-ла против РСВ (паливизумаб), -зарегистрированный в Российской Федерации в феврале 2010 г. для пассивной иммунопрофилактики РСВ-инфекции у детей групп риска. Во всем мире паливизумаб (Синагис, Эбботт Лэбораториз) эффективно используется у пациентов групп риска уже много лет, фактически являясь средством сезонной пас-сивной иммунизации для этих детей. Препарат заре-гистрирован более чем в 60 странах мира и включен в рекомендации и стандарты медицинской помощи недо-ношенным детям, рожденным до 35-й нед гестации, детям с БЛД и ВПС [25, 26] . Паливизумаб представляет собой гуманизированные моноклональные антитела IgG 1 , взаи-модействующие с эпитопом A антигена белка слияния (белок F) РСВ. В исследованиях на взрослых доброволь-цах паливизумаб имел фармакокинетический профиль, аналогичный профилю человеческих антител IgG 1 . Кроме того, паливизумаб не вызывает развитие толерантно-сти. В России показанием к применению паливизумаба является профилактика тяжелой инфекции нижних дыха-тельных путей, вызванной РСВ, у детей с высоким риском заражения данным вирусом: в возрасте до 6 мес, рожденных на 35-й нед беремен-• ности или ранее; в возрасте до 2 лет, которым требовалось лечение • по поводу БЛД в течение последних 6 мес (данная терапия может включать в себя дополнительный кис-лород, системные и/или ингаляционные кортикосте-роиды, системные и ингаляционные бронходилатато-ры, диуретики); в возрасте до 2 лет с гемодинамически значимыми • ВПС [27] . Паливизумаб -единственный на сегодняшний день специфический препарат для профилактики РСВ-инфек-ции, который доказал свою эффективность в много-центровых рандомизированных контролируемых иссле-дованиях. В метаанализ [11] данных о госпитализации пациентов с РСВ-инфекцией, опубликованных в 2011 г., было включено 8542 ребенка, из которых 4543 полу-чали иммунопрофилактику паливизумабом, а 3999 -не получали. Показатели общей смертности были оце-нены на основании данных о 13849 детях, из которых 7019 получали паливизумаб, а 6830 -плацебо (табл. 3, рис. 3 а, б). Таким образом, паливизумаб может при- Недоношенные дети с гестационным возрастом < 32 нед 4,3 2,9
Дети с бронхолегочной дисплазией 1,5 2,0
Дети с врожденными пороками сердца 1,3 1,8
Таблица 3. Снижение показателей (в число раз) общей смертности и госпитализации с РСВ-инфекцией при использовании паливизумаба [11] меняться с целью снижения младенческой смертности и госпитализаций по поводу РСВ-инфекции у недоно-шенных детей и детей из других групп риска. Кроме того, накапливается все больше сведений о возможном снижении риска развития бронхиальной астмы в отда-ленном периоде при использовании данного препарата у детей из групп риска [28] . Небольшой отечественный опыт иммунопрофилактики паливизумабом подтвердил эффективность и безопасность препарата [29, 30] . В 2011 г. Департаментом здравоохранения города Москвы было принято решение о проведении целена-правленной иммунопрофилактики РСВ-инфекции у детей групп высокого риска (глубоконедоношенных детей с БЛД и детей первых месяцев жизни с врожденными пороками сердца), родившихся в лечебно-профилактических учреж-дениях города Москвы.
В рамках реализации московской городской про-граммы в эпидемический сезон 2011-2012 г. 156 детей из групп риска впервые в России получали иммунопро-филактику РСВ-инфекции паливизумабом за счет бюд-жетных средств.
Целью данного исследования является анализ эффек-тивности и безопасности паливизумаба в профилактике РСВ-инфекции нижних дыхательных путей у детей групп высокого риска в рамках реализации пилотной регио-нальной программы.
ПАЦИЕНТЫ И МЕТОДЫ
Дизайн исследования: открытое неконтролируемое исследование.
Критерии включения: 1) дети в возрасте до 6 мес, рожденные на 35-й нед беременности или ранее; 2) дети в возрасте до 2 лет с БЛД; 3) дети в возрасте до 2 лет с гемодинамически значимы-ми ВПС. Таким образом, паливизумаб назначался в соответ-ствии с зарегистрированными показаниями для приме-нения.
Характеристика пациентов. Пациенты (80 мальчи-ков, 76 девочек), получавшие паливизумаб, были раз-делены на три группы в зависимости от риска тяжелого течения РСВ-инфекции (табл. 4, 5). Рис. 3а. Снижение частоты госпитализации детей из всех групп риска при иммунизации паливизумабом [11] (результаты мета-анализа 10 исследований более 8000 детей) Рис. 3б. Снижение общей смертности у детей групп риска при иммунизации паливизумабом [11] Среди иммунизированных пациентов одно введение препарата получили 7 (4,5%), два введения -9 (5,8%), три введения -139 (89,1%), четыре введения -1 (0,6%). Таким образом, большинство пациентов (140 детей, 89,7%) завершили иммунизацию паливизумабом, полу-чив 3 и более введений препарата; у 16 детей курс иммунизации оказался неоконченным в связи с отказом родителей от дальнейшего участия без указания при-чин. Последующий анализ эффективности и безопас-ности иммунопрофилактики паливизумабом проводился на основании данных о 140 пациентах, получивших 3 и более введений, -46 недоношенных детей без БЛД, 76 детей с БЛД и 18 детей с ВПС без БЛД.
Эффективность паливизумаба оценивалась по изме-нению следующих показателей:
частота ИНДП (бронхиолит, обструктивный бронхит, • бронхит, пневмония, вирус-индуцированное обостре-ние БЛД) в течение 3 мес до и 3 мес после начала иммунопрофилактики паливизумабом; частота госпитализаций в связи с ИНДП в течение • 3 мес до и 3 мес после начала иммунопрофилактики паливизумабом; частота ИНДП РСВ-этиологии в течение 3 мес после • начала иммунопрофилактики паливизумабом. Частоту ИНДП и госпитализаций в связи с ними рас-считывали как отношение числа данных событий к про-изведению числа пациентов на время наблюдения в месяцах до и после иммунизации (420). Оценка эффек-тивности препарата на основании сравнения частоты клинически значимых эпизодов заболевания в период, предшествующий введению лекарственного средства, и аналогичный по продолжительности период после вве-дения является общепринятой практикой в отношении препаратов моноклональных антител, к которым относит-ся паливизумаб [31] .
Для исключения РСВ-этиологии у пациентов, имму-низированных паливизумабом и госпитализированных с Иммунопрофилактика и иммунотерапия в педиатрии ИНДП, с момента введения первой дозы паливизумаба и до 30 дней после введения последней дозы исследовал-ся назофарингеальный смыв на РСВ посредством имму-нохроматографического экспресс-теста -РСВ Quick Stripe TM (Savyon Diagnostics Ltd., Израиль). В период, предшествующий началу иммунопрофилактики паливизу-мабом, этиология ИНДП не определялась. Безопасность и переносимость паливизумаба оце-нивали на основании нежелательных явлений, разви-вавшихся с момента введения первой дозы препарата и до 30 дней после введения последней дозы.
РЕЗУЛЬТАТЫ И ИХ ОБСУЖДЕНИЕ Эффективность. Анализ частоты ИНДП и госпита-лизаций в связи с ними в эпидемический сезон 2011-2012 г. у детей, включенных в исследование, проде-монстрировал преобладание данных случаев до начала иммунизации -в период с ноября 2011 г. по январь 2012 г. (табл. 6). За эти 3 мес было отмечено 27 случаев ИНДП у 140 детей из групп риска: 7 -у недоношенных детей без БЛД, 18 -у детей с БЛД и 2 -у детей с ВПС без БЛД. Из 27 случаев ИНДП госпитализацией в этот период закончились 20: у 4 недоношенных детей без БЛД, у 14 детей с БЛД и у 2 детей с ВПС.
Полученные результаты (табл. 7) свидетельствуют о высокой частоте ИНДП и госпитализаций в связи с ними у детей групп риска тяжелого течения РСВ-инфекции, составившей, по нашим данным, 15,2 и 8,7% у недоно-шенных детей без БЛД, 23,7 и 18,4% -у детей с БЛД, по 11,1% -у детей с ВПС, соответственно, что согласует-ся с данными литературы [32, 33] .
По контрасту с этими показателями в период от нача-ла программы иммунопрофилактики РСВ-инфекции (февраль-май 2012 г.) частота ИНДП и госпитализаций в связи с ними существенно уменьшилась -зарегистри-ровано 6 и 4 случаев, соответственно: 2 ИНДП, закон-чившиеся госпитализациями, у недоношенных детей и 4 ИНДП, из которых 2 закончились госпитализациями, у детей с БЛД. Дети с ВПС после иммунизации не болели. Необходимо отметить, что ни в одном случае у пациен-тов, иммунизированных паливизумабом, госпитализа-ция не была связана с РСВ-инфекцией. Это подтверж-дено результатами исследования назофарингеального смыва на РСВ посредст вом иммунохроматографическо-го экспресс-теста. Также не было отмечено летальных исходов.
В табл. 7 представлены данные о частоте ИНДП и госпи-тализаций в связи с ними в течение 3 мес до и 3 мес после иммунизации (среднемесячная частота событий из расчета на 1000 пациентов за указанный период) у детей из разных групп риска, получавших иммунопрофилак-тику РСВ-инфекции паливизумабом. Можно видеть, что иммунизация препаратом привела к снижению частоты ИНДП у детей всех групп риска в 4,57 раза, госпитали-заций в связи с ИНДП -в 4,8 раза (рис. 4а). При этом максимальная эффективность иммунизации была уста-новлена у детей с БЛД, у которых данные показатели сни-жались в 4,39 и 6,8 раз, соответственно. Частота ИНДП у недоношенных детей без БЛД снизилась в 3,64 раза, частота госпитализаций в связи с ИНДП -в 2,1 раза. Показательным является также снижение частоты ИНДП у детей с ВПС -после использования паливизумаба случаев ИНДП у данной категории пациентов вообще не отмечено (рис. 4б).
Таким образом, паливизумаб в данном исследова-нии, как и в ранних отечественных и крупных иссле- Примечание. * -на 1000 пациенто-месяцев; БЛД -бронхолегочная дисплазия; ВПС -врожденный порок сердца.
до ваниях других стран [29, 30] , продемонстрировал свою эффективность в отношении снижения частоты ИНДП и госпитализаций в связи с ними у детей групп риска, а также в предотвращении ИНДП РСВ-этиоло гии. Это особенно важно в связи с высокой потребностью таких пациентов в стационарном лечении, интенсивной и оксигенотерапии при развитии ИНДП, как было указа-но ранее (см. табл. 1).
Безопасность использования паливизумаба оцени-валась по наличию/отсутствию нежелательных явлений. Всего из 140 пациентов, получивших 420 инъекций пре-парата, у 34 пациентов было зарегистрировано 57 неже-лательных явлений, частота которых не превышала ука-занные в инструкции по применению препарата (табл. 8). Не было зарегистрировано серьезных нежелательных явлений, общих и местных реакций на введение препара-та. Нежелательные явления носили легкий/среднетяже-лый характер, ни в одном случае их нельзя было связать с использованием паливизумаба.
Таким образом, у включенных в анализ пациентов паливизумаб показал высокий профиль безопасности. Ранее было установлено, что частота побочных эффектов применения паливизумаба сопоставима с таковой при назначении плацебо [27] . ЗАКЛЮЧЕНИЕ Внедрение современных перинатальных технологий, широкое использование методов интенсивной тера-пии в лечении недоношенных новорожденных приве-ло к существенному увеличению выживаемости детей с ЭНМТ и ОНМТ. В Российской Федерации в 2012 г. будет завершен начатый в 1992 г. поэтапный переход на критерии живорождения и мертворождения, реко-мендованные экспертами Всемирной организации здра-воохранения. Можно ожидать дальнейшего увеличения выживаемости данной категории детей, требующих окси-генотерапии в возрасте 28 сут жизни и старше (детей с БЛД). Следовательно, увеличится число детей с высо-ким риском развития тяжелых форм респираторных инфекций, в частности РСВ-инфекции.
С 2010 г. в нашей стране разрешен к применению высо коэффективный и безопасный препарат пассив-ной иммунопрофилактики РСВ-инфекции у детей групп риска -паливизумаб (Синагис). Пилотная программа (1, 2) . Although RSV infection is a serious threat to all infants, certain infants are at high risk for severe respiratory disease (3,4), i.e., those born prematurely (Ͻ36 wks gestational age) and those with chronic lung disease (CLD) of prematurity (also called bronchopulmonary dysplasia), congenital heart disease (CHD), neuromuscular disease, or immune deficiencies. Such infants are more often severely compromised by RSV lower respiratory tract illness resulting in hospitalization, often with admission to an ICU and the need for assisted ventilation. It is in these situations that the pediatric critical care practitioner would most commonly encounter the morbidity and mortality associated with RSV infection.
Reported RSV-associated mortality rates vary from 0% to 37% (5-11). In select groups of infants at high risk (e.g., premature infants Ͻ36 wks gestational age or those with CLD or CHD), noticeable mortality and increased morbidity may occur from this infection (12, 13) . The mortality rate is Ͻ1% in previously healthy infants, but has been reported as high as 5% in high-risk groups (10) .
Palivizumab is a monoclonal antibody indicated for prophylaxis against RSV infection in certain infants and children at high risk. The safety and efficacy of palivizumab have been established in premaObjectives: A systematic literature review and meta-analysis was performed to evaluate the impact of prophylaxis with palivizumab on mortality and morbidity associated with respiratory syncytial virus infection in infants at high risk (<35 wks of gestational age, chronic lung disease, or congenital heart disease).
Data Sources: MEDLINE, EMBASE, and Current Contents were used. MEDLINE was searched from January 1, 1990 to May 16, 2007. The bibliographies of accepted studies and recent reviews and proceedings from the past 2 yrs were searched to identify additional relevant studies.
Study Selection: Randomized controlled trials and prospective or retrospective cohort studies evaluating all-cause and respiratory syncytial virus-specific mortality, respiratory syncytial virus hospitalizations, and health care use in infants at high risk for respiratory syncytial virus infection receiving prophylaxis with palivizumab.
Data Extraction: Data elements from each accepted study were extracted by one researcher and confirmed by a second researcher. Differences were resolved before data entry and analysis.
Data Synthesis: A total of 2473 citations were screened and ten comparative studies of palivizumab prophylaxis evaluating >15,000 infants were included. Comparisons of mortality and hospitalization outcomes between infant groups using prophylaxis and not using prophylaxis were made using meta-analyses.
Conclusions This study was sponsored and funded by Med Immune, LLC, the manufacturer of palivizumab. Physicians World, a division of KnowledgePoint360 Group, LLC, and John E. Fincke, PhD, and Gerard P. Johnson ture infants and children with CLD or hemodynamically significant CHD (4, 14) . A systematic review of published studies and meeting abstracts was conducted and meta-analyses of outcomes were performed to examine the value of prophylaxis with palivizumab in infants at high risk for severe RSV infection. The primary end points evaluated were allcause and RSV-specific mortality in infants who received prophylaxis with palivizumab compared with infants who did not receive prophylaxis. Secondary end points include RSV hospitalizations and other resource use variables, such as emergency department and ICU admissions, hospital and ICU length of stay, oxygen requirements, apnea episodes, outpatient visits, and use of mechanical ventilation.
METHODS
Literature Search
A literature search was conducted using MEDLINE (via PubMed), EMBASE, and Current Contents. MEDLINE was searched from January 1, 1990 through May 16, 2007, using the following search Medical Subject Headings and limits: "respiratory syncytial virus infections" OR "respiratory syncytial virus, human;" "limits: human, all infant: birth-23 months" OR "neonate" OR "neonates" OR "premature." The literature search started with 1990 to encompass fully any data published before palivizumab was approved by the Food and Drug Administration in 1998. A manual review of all accepted studies and recent reviews was performed to supplement the electronic searches and identify additional relevant studies. Proceedings from the past 2 yrs of professional meetings were searched for relevant abstracts; it was assumed that presentations before this period would be published.
Study Selection
Abstracts were reviewed for exclusion criteria, including: studies not conforming to the original search criteria; case reports, letters, comments, editorials, and reviews; studies published in languages other than English, French, German, Italian, or Spanish; studies in infants with human immunodeficiency virus, cystic fibrosis, or immunodeficiency; prophylaxis with agents other than palivizumab; studies of mixed (with and without prophylaxis) groups of infants in which outcomes for each group could not be separated; and epidemiologic studies. A full list of inclusion and exclusion criteria is shown in Supplemental Digital Content 1 (http://links.lww.com/PCC/A28). The full manuscripts of accepted abstracts underwent a more in-depth review to satisfy the following requirements: reporting ten or more patients per study group; age up to 24 months at enrollment; and any of the outcomes of interest (primary or secondary) described. All manuscripts accepted or rejected during the review process required the consensus of two investigators. Data elements contained within the manuscripts from each accepted study of infants at high risk reporting outcomes of interest in comparable groups of infants with and without prophylaxis were extracted by one researcher to a data extraction form and independently confirmed by a second researcher. A full list of data elements sought from each accepted study is shown in Supplemental Digital Content 2 (http://links.lww.com/PCC/A29). Discrepancies were resolved before data entry by third-party arbitration. All extracted data were entered into MetaHub (United Biosource Corporation, Lexington, MA). The entered data were verified for accuracy and consistency by comparison with the extraction forms before locking the database for analysis.
Study Quality
All included studies were evaluated for level of evidence using a framework developed by the Centre for Evidence-Based Medicine, Oxford, UK (15) . All randomized controlled trials (RCTs) were evaluated for study quality using the Jadad scoring system (16).
Study Outcomes
Relevant data extracted included characteristics of the study, patient demographics, and baseline characteristics. The primary end points were all-cause and RSV-related mortality. Secondary end points were RSV hospitalizations, emergency department and ICU admissions, hospital and ICU length of stay, oxygen requirements, apnea episodes, outpatient visits, and use of mechanical ventilation. Mortality and morbidity outcomes occurring during the first RSV season were captured. Study investigators were contacted to obtain mortality data in cases in which this information was unavailable in the published study.
Statistical Methods
Study, patient, and treatment group data were summarized using descriptive statistics. Treatment groups were determined a priori. For outcomes data, mean percentages (weighted by treatment arm size) were calculated for the all-preterm group, which included the following infant subgroups: Յ32 wks gestational age, 32-35 wks gestational age, infants with CLD, infants with CHD, and premature infants in mixed groups (any infant Ͻ35 wks gestational age with outcomes that could not be separated for specific gestational age groups of interest), for the subgroups themselves, and for infants with CHD. Numbers of infants enrolled or randomized were used as denominators for mortality and hospitalization rates. Odds ratios (ORs) for nonmortality outcomes were estimated using a random-effects meta-analytic model. For mortality, a fixed-effects model using Peto ORs was chosen because of the superiority of this approach for meta-analyses of data with rare events (17) . Heterogeneity was tested using Cochrane's Q-statistic. All calculations were performed using SAS software version 9.1 (SAS Institute, Cary, NC) and SPSS software version 15.0 (SPSS, Chicago, IL). Sensitivity analyses comparing results from RCTs with nonRCTs were conducted post hoc for all outcomes to examine the influence of the respective study design on the overall result. Post hoc analyses of the numbers needed to be treated to prevent one all-cause mortality or RSV hospitalization were also conducted. The lack of available data for the other end points precluded the same analyses for those end points.
RESULTS
The literature search yielded 2,473 unique citations that were screened further (Fig. 1) . A total of 1,944 abstracts were rejected during initial screening for obvious protocol-specified exclusion criteria (e.g., reviews, no RSV infection or prophylaxis, no population of interest, age older than 24 months) and 433 manuscripts were rejected during the second screening process. Of the 49 manuscripts reporting prophylaxis against RSV, 38 were rejected because they reported only single-arm studies. One of the remaining 11 manuscripts (18) was excluded from the analyses because of methodological concerns: the study groups were not comparable at baseline and data adjusting for differences between groups were not reported. The final dataset included ten manuscripts reporting comparative studies, which are the focus of this review and analyses. As shown in Table 1 , not all of the manuscripts provided data for both mortality and RSV hospitalizations.
Secondary end points other than RSV hospitalizations (emergency department and ICU admissions, hospital and ICU length of stay, oxygen requirements, apnea episodes, outpatient visits, and use of mechanical ventilation) were not included in the meta-analyses because data, when available, generally were provided from one to two studies, preventing a formal meta-analysis.
Study Characteristics
Characteristics of all comparative studies from accepted manuscripts are detailed in Table 1 (4, 14, 19 -26) . The ten studies evaluated approximately 15,000 infants (approximately 12,000 in studies reporting mortality). Three of these studies (1316 infants) were conducted in North America (22, 25, 26) , four studies (4437 infants) were conducted in Europe (19, 20, 23, 24) , two studies (2789 infants) were conducted in multiple countries (4, 14) , and one study (6302 infants) was conducted in Japan (21) . Three studies were RCTs (2831 infants), all of which were of high quality, had a Jadad score of 5, and provided a high level of evidence (4, 14, 25) . The remaining studies were prospective or retrospective comparative cohort studies (level of evidence, 2B) (19 -24, 26) ; one study (21) was a questionnaire survey soliciting detailed information on case report forms. Five studies were industry-sponsored. Most studies focused on or reported subgroup data for infants with CLD; another common risk group was premature infants Յ32 wks gestational age. One study focused only on infants with CHD (1287 infants) (14) . ACM, all-cause mortality; CLD, chronic lung disease; GA, gestational age; LoE, level of evidence; RCT, randomized controlled trial; RSVM, respiratory syncytial virus-related mortality; RSVH, respiratory syncytial virus-related hospitalization.
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Additional data were provided by the investigators from three studies (4, 21, 22) .
Infant Characteristics
Baseline characteristics of infants are summarized in Table 2 . In general, the study groups appeared comparable at baseline with the exception of CLD comorbidity (prophylaxis, 30%; no prophylaxis, 13%). A similar proportion of infants were enrolled in the groups with and without prophylaxis. Additionally, 60% and 34% of infants receiving prophylaxis had a family history of atopic diseases and smoking, respectively; in the group without prophylaxis, the corresponding numbers were 52% and 32%, respectively. The majority of infants in both groups (78% and 86%, respectively) were single births.
Outcomes
Mortality outcomes were reported in seven studies (4, 14, 21-23, 25, 26) . Table 3 and Figure 2 present all-cause mortality rates among infants who received prophylaxis with palivizumab and those who did not; a graphic representation of the allcause mortality rates presented by study is given in Supplemental Digital Content 3 (http://links.lww.com/PCC/A30). Overall, the mortality rate for all causes occurring during the first RSV season was 0.19% for the preterm group with prophylaxis and 0.53% for the preterm group without prophylaxis (Peto OR, 0.30; 95% confidence interval [CI], 0.17-0.55). Similarly, rates for the different subgroups of the preterm cohort when mortality was reported were: CLD: prophylaxis, 0.22%; no prophylaxis, 0.34% (Peto OR, 0.83; 95% CI, 0.13-5.25); preterm Յ32 wks gestational age with prophylaxis, 0.23%; preterm Յ32 wks gestational age with no prophylaxis, 0.99% (Peto OR, 0.25; 95% CI, 0.13-0.49); preterm 32-35 wks gestational age with prophylaxis, 0.09%; preterm 32-35 wks gestational age with no prophylaxis, 0.13% (Peto OR, 0.22; 95% CI, 0.03-1.89); CHD with prophylaxis, 3.29%; and CHD with no prophylaxis, 4.17% (Peto OR, 0.78; 95% CI, 0.44 -1.39). The results were statistically significant (p Ͻ.01) favoring palivizumab prophylaxis for the all-preterm cohort, which combined the different preterm (Յ32 wks gestational age, 32-35 wks gestational age, mixed preterm) and CLD subgroups. The results were also significant for premature infants Յ32 wks gestational age. For the others (32-35 wks gestational age, mixed preterm, CLD, and CHD), the results revealed a consistent albeit statistically nonsignificant trend. Infants who received palivizumab for RSV prophylaxis had a lower all-cause mortality rate than those infants who did not receive prophylaxis. A sensitivity analysis comparing RCTs vs. nonRCTs showed that all-cause mortality in the premature cohort was similarly reduced, nonRCT (19 -24, 26) had an OR of 0.32 (95% CI, 0.15-0.58) and RCT (4, 25) had an OR of 0.32 (95% CI, 0.09 -1.20); however, the results were not statistically significant for the RCT groups. Tests for heterogeneity were not performed for mortality analyses because the extremely low rate of events reduced the power of these tests to levels at which the results would not be informative. The number needed to treat with palivizumab to prevent one allcause death ranged from 113 to 1736, depending on the subgroup (Table 4) .
The cause of death was not always reported. Deaths reported attributable to RSV were rare: three of 6358 in the prophylaxis and two of 6162 in the no prophylaxis groups for all-preterm infants (OR, 1.22; 95% CI, 0.20 -7.38), and two of 639 in the prophylaxis and four of 648 in the no prophylaxis group for CHD infants (OR, 0.52; 95% CI,0.10 -2.58). However, because of the low numbers of deaths reported, these data should be interpreted with caution.
RSV-related hospitalization data were included in a meta-analysis (Table  4 and Fig. 3 and by study in Supplemental Digital Content 4, please see http://links.lww.com/PCC/A31). The RSV hospitalization rates ranged from 2.2% to 7.3% among infants administered prophylaxis, with the largest proportion of hospitalizations occurring among infants with CLD. Similar hospitalization trends were observed among infants not administered prophylaxis, but the rates were much higher, ranging from 7.3% among the mixed preterm infants group to 15% in infants with CLD. Comparative metaanalyses revealed significantly (p Ͻ .01) lower hospitalization rates across all subgroups of infants who received prophylaxis with palivizumab. Table 5 also presents the p value for the Cochrane Q-statistic for the test of heterogeneity. In the two RCTs of preterm infants (4, 25) in which hospitalizations were the primary end points, palivizumab resulted in a significant reduction of RSV hospitalizations among preterm infants receiving prophylaxis (OR, 0.42; 95% CI, 0.27-0.64). The results remained significantly in favor of palivizumab prophylaxis when RCTs were excluded from analyses (OR, 0.33; 95% CI, 0.22-0.48). As described, one study by Lacaze et al (18) was not included because of methodological concerns. A post hoc analysis including this study showed no relevant change in results for RSV hospitalization; for the all-preterm group with the study included vs. study not included, the OR was 0.34 (95% CI, 0.26 -0.44) vs. 0.30 (95% CI, 0.17-0.55), respectively. Similarly, for the Յ32 wks gestational age subgroup, the OR was 0.29 (95% CI, 0.23-0.37) vs. 0.25 (95% CI, 0.13-0.49), respectively. The number needed to treat with palivizumab to prevent one RSV hospitalization ranged from 11 to 24, depending on the subgroup (Table 4 ). Other secondary end point data were either not reported (emergency department admissions, apnea episodes, outpatient visits) or sparse (many from one or two studies; ICU admissions, hospital and ICU length of stay, oxygen requirements, and use of mechanical ventilation).
DISCUSSION
The aim of this systematic literature review and meta-analysis was to estimate Figure 2 . Meta-analysis of all-cause mortality. CHD, congenital heart disease; CLD, chronic lung disease; GA, gestational age. tests for heterogeneity were not performed because they would be of no value due to the rarity of events.
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the effect of palivizumab prophylaxis on mortality, RSV hospitalizations, emergency department and ICU admissions, hospital and ICU length of stay, oxygen requirements, apnea episodes, outpatient visits, and use of mechanical ventilation. To our knowledge, this is the first systematic review of the effect of prophylaxis with palivizumab on mortality. Our findings show a statistically significant beneficial effect of palivizumab prophylaxis on all-cause mortality. Confidence in this finding is limited by the nonrandomized nature of many of the studies included in the analysis, and by the many factors in addition to RSV that could affect mortality. The actual cause of death was unknown in many cases. Nevertheless, the group receiving prophylaxis had a greater frequency of underlying illnesses such as CLD, which might be expected to increase their risk for a fatal outcome. Although not statistically tested, the prophylaxis group had a slightly lower mean gestational age and mean birth weight, and the no prophylaxis group had a slightly lower mean age at baseline. This suggests that the infants who received prophylaxis are at higher risk for mortality than the infants who did not receive prophylaxis. Despite this difference, we observed an effect favoring prophylaxis. The postneonatal mortality rate for preterm infants reported by the Centers for Disease Control and Prevention is 2.7% for infants Ͻ32 wks gestational age and 0.5% for infants 32-35 wks gestational age, with an overall rate of 0.9% for infants Յ35 wks gestational age (27) , which is greater than the mortality rate in the no prophylaxis groups in our study. This suggests that infants enrolled in these studies may be healthier than the broader infant population. The mortality rate for infants at high risk with CHD reported in one study was much higher, 3.3% and 4.2% among infants with and without prophylaxis, respectively (14) .
All-cause mortality could be related to the increased rate of RSV hospitalizations in the group not receiving prophylaxis. It is clear that simply being admitted to the hospital increases risk (28) . Once hospitalized, these infants are increasingly vulnerable to death from multiple causes, including nosocomial infection (29) , complications of medical procedures, and medication errors. Measures that prevent RSV hospitalization should also logically reduce RSV ICU admission rates. Even if excess deaths in the group not receiving prophylaxis are not directly related to RSV infection, it is clinically important to recognize the significance of reducing mortality (from any cause) by preventing RSV-related hospitalization and admission to the ICU. The fact that there was a decrease in all-cause mortality compared with RSV-specific mortality in the prophylaxis group is not surprising. Not all studies reported RSV-specific mortality data. Mortality specifically attributed to RSV infection may be difficult to ascertain, because most pediatric patients do Figure 3 . Meta-analysis of respiratory syncytial virus hospitalizations. CHD, congenital heart disease; CLD, chronic lung disease; GA, gestational age. Finally, pediatric patients admitted to the pediatric ICU with severe RSV disease are often placed on mechanical ventilation support (29) , which may increase the risk of nosocomial infection from ventilator-associated pneumonia (30). Prevention of this cascade of events in these infants invariably leads to decreased morbidity and mortality. Elward et al (31) have demonstrated that children with ventilator-associated pneumonia had a significantly longer mean pediatric ICU length of stay than those without ventilator-associated pneumonia (27 days vs. 6 days) and higher mortality rates (20% vs. 7% with and without ventilator-associated pneumonia, respectively). Many children admitted to a pediatric ICU with the diagnosis of RSV infection, once intubated, may be more likely to have progression to bacterial superinfection, sepsis, septic shock, and multiorgan failure. Any of these issues may result in a proximal cause of death yet directly result from the original severe RSV disease. It is important to highlight that of the nine deaths in the IMPact-RSV study (4) , four occurred in the hospital setting with the following causes: pneumococcal sepsis (n ϭ 1), complications of extracorporeal membrane oxygenation (n ϭ 1), and complications of RSV (n ϭ 2). The remaining five deaths occurred at home, and three of these were attributable to sudden infant death syndrome. All these factors emphasize the need for better understanding of the cause of death in these patients.
Children with prematurity and subsequent CLD represent an important population in any pediatric ICU. Therefore, it is important to address the impact of RSV infection in this population. A retrospective cohort study by Forbes et al (2) reported ICU admission rates attributable to RSV of 22%, 13%, 20%, and 22% for infants with CHD, CLD, early preterm birth (Յ32 wks gestational age), and late preterm birth (33-36 wks gestational age), respectively, compared with a rate of 10% for term infants (Ն37 wks gestational age). Another retrospective cohort study of infants with RSV pediatric ICU admissions by Thorburn et al (29) reported an overall mortality rate of 8.6%, all (n ϭ 35) of whom had at least one preexisting condition (cardiac lesion, chromosomal abnormality, CLD, immunodeficiency, large airway abnormality, or neuromuscular disorder). The mortality rate in the current analysis in the Յ32 wks gestational age group not receiving prophylaxis (0.99%) was greater than that of the CLD group not receiving prophylaxis (0.34%). The CLD group had a lower beneficial effect of immunoprophylaxis in the clinical trial compared with the preterm group, and therefore could be expected to be at a greater risk for mortality (4) . There may be various reasons for this. First, the Յ32 wks gestational age group also included the Ͻ28 wks gestational age group, which had a higher risk of mortality, reported to be 6.2% by the Centers for Disease Control and Prevention (27) . Second, the CLD group had a greater proportion of infants receiving prophylaxis (CLD, 70%; Յ32 wks gestational age, 55%). Third, the total number of infants with CLD not receiving prophylaxis evaluated across studies (n ϭ 585) was lower than that of the Յ32 wks gestational age group (n ϭ 2827) and, for a rare event like mortality, this could introduce random error.
This analysis also confirms the benefit of prophylaxis with palivizumab regarding a reduction in RSV hospitalizations, which was observed across all infant risk groups. The current findings are consistent with those from the palivizumab registration trials (4, 14) in which RSV hospitalization was the primary efficacy end point. In the first study, IMPact-RSV (4), evaluating premature infants born at Յ35 wks gestational age with or without CLD, the RSV hospitalization rate was reduced by 55%. The most common adverse events reported in this study (occurring Ն1% more frequently in palivizumab vs. control patients) were upper respiratory infection, otitis media, fever, and rhinitis (4). In the second study of infants with hemodynamically significant CHD, palivizumab reduced RSV-related hospitalizations by 45% (14) . Furthermore, in a recent publication of the 4-yr Palivizumab Outcomes Registry data (32), the authors report that the RSV hospitalization rate among palivizumab recipients was 1.3%, which is even lower than the rate observed in clinical trials.
There are several important limitations of our study. Strength of evidence is important in the interpretation of results of any systematic review. This issue becomes more of a challenge when different study designs are accepted (33). In our data set, there were only three randomized trials; seven other studies were observational. Inclusion of retrospective studies with historical controls may introduce bias in mortality and hospitalization rates; however, these were the best data available at the time of this analysis. Of the three RCTs, none was designed to evaluate the effect of RSV prophylaxis on mortality as an end point. Also, for some of the studies, additional data not present in the manuscript were collected from the authors and these data cannot be validated (4, 21, 22) . Further study in prospective and randomized trials would be ideal.
To design such a study would be considerably difficult. Sample size calculations indicate that to have 90% power to detect a difference in mortality rate between placebo and palivizumab using the underlying rates similar to those found in this meta-analysis (0.5% for placebo and 0.2% for palivizumab), it would require approximately 18,000 patients with 9000 patients per study arm. Given these numbers, it is not feasible to conduct an RCT solely to explore the effect of prophylaxis on mortality. Furthermore, infants who are at high risk for severe RSV disease are recommended to receive prophylaxis (3, 34 -37). To select a group of infants to receive placebo would pose ethical challenges. A meta-analysis seemed to be the best-suited method to understand this research question. Data for additional morbidity outcomes were not reported or scant, and no analyses were possible. Because proceedings data from only the previous 2 yrs were included in the search, findings that were not published for any reason before that time would not have been included in the analysis. Thus, publication bias is another potential limitation of this analysis.
In conclusion, prophylaxis with palivizumab was associated with a reduction in all-cause mortality and RSV hospitalizations. Meta-analysis revealed that palivizumab prophylaxis is an effective measure in preventing severe RSV infection and reducing the burden of this disease in infants at high risk. However, these findings are based primarily on observational data. The reduction in all-cause mortality is a provocative finding, but one that may be difficult to further substantiate given the ongoing advances in care and the rarity of this end point. 19 . 
Introduction
Respiratory syncytial virus (RSV) is currently considered the single most important cause of childhood respiratory infection.
1,2 The World Health Organization reports four million deaths annually worldwide among children aged ,5 years due to the virus. 3 The primary cause of severe lower respiratory tract infection (LRTI) globally among infants aged ,2 years, the virus is the leading cause of hospitalizations for a LRTI during respiratory virus season. Premature infants with underdeveloped lungs and an immature immune system are particularly vulnerable to serious infections from RSV. 1, 2, [4] [5] [6] The transmission of RSV is difficult to prevent because it is easily 
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Tatochenko et al transmitted by unprotected coughing or sneezing, or contact with contaminated hands. 7 As many as 60% of all children are infected with RSV in their first year of life and almost 100% within their second year of life. 8 RSV does not stimulate a robust immunological response, therefore reinfection is common. 9 Unfortunately, once children are infected with the virus, there are no etiopathogenetic treatment options available. Routine use of bronchodilators, epinephrine, steroids, and ribavirin has proven to be of no significant benefit; therefore, treatment has been limited to supportive measures. 10 Palivizumab (Synagis ® ; MedImmune Inc, Gaithersburg, MD; marketed outside the USA by Abbott Laboratories, Abbott Park, IL) is a humanized IgG1 monoclonal antibody targeting the F protein of RSV. When administered monthly while RSV is circulating in the community, palivizumab has been shown to reduce severe RSV disease requiring hospitalization in high-risk children (ie, those born #35 weeks gestational age; those with bronchopulmonary dysplasia; and infants with hemodynamically significant congenital heart disease who were less than two years of age at the start of RSV season), by approximately 50% compared to placebo. 11, 12 Approved in the United States in 1998, palivizumab received European approval in 1999, and its approval in the Russian Federation was received in February 2010. Optimal timing of prophylaxis is based on epidemiological data.
A review of literature published over a 30-year period regarding RSV seasonality and epidemiology disclosed that RSV season in the northern hemisphere roughly starts in September and ends in April. 5, 6 European countries, including those countries near Russia, with published data, had similar RSV seasons that started as early as September, and ended as late as July. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] In the Nordic countries of Finland, Denmark, Norway, and Sweden, RSV season begins in October or November and continues through March or April, with peak activity in December/January. 5, 18, 25 In Norway, RSV has been reported through June, with later peak activity in January/ February.
14 Although the Russian Federation covers a very large territory, including arctic areas and subtropics, most of its population occupies temperate regions.
The objective of this study was to describe the prevalence and seasonality of RSV infection in children aged #2 years, hospitalized for LRTI between September 2008 and April 2009, in three temperate regions of the Russian Federation. Demographic information, morbidity, and risk factors are also reported.
Methods
This prospective, multicenter, observational study was conducted at nine participating hospital centers located in three regions: seven in Moscow (Central), one in Saint Petersburg (Northwest), and one in Tomsk (East). The study included parental written informed consent and received approval from the Institutional Ethics Boards of all participating centers. The timing of the study, from September 2008 through April 2009, allowed essential epidemiological information on RSV to be obtained during the cold season in the northern hemisphere when RSV is most prevalent. The plan was to enroll approximately 500 eligible children into the study over the period.
study population
All children with LRTI hospitalized at participating centers were potentially eligible for enrollment. The determination of LRTI was based on a medical diagnosis of acute bronchiolitis, bronchitis, and/or pneumonia, and based on the presence of symptoms (cough, coryza, rhinorrhea, fever, or retractions) and signs (wheezing, crackles, or rales). Children with at least one symptom and a chest radiograph diagnostic of bronchiolitis, pneumonia, or bronchitis were also designated as having an LRTI. Additionally, apneic events with accompanying auscultatory findings, chest radiograph of LRTI, clinical symptoms of fever, or coryza were designated an LRTI episode.
Eligibility requirements also included age #2 years at the time of hospital admission and hospitalization ,24 hours prior to RSV testing. Enrollment was prohibited if the child had received any product containing RSV-neutralizing antibodies (including hyperimmunoglobulins) within 100 days of enrollment, or had participated in a clinical trial for RSV treatment or prophylaxis prior to or during the hospitalization.
Procedures
Physical examination was performed and a parent provided information regarding the child's personal and family medical and social history during a single screening and enrollment visit prior to RSV testing. The RSV diagnostic test method utilized was approved for use by regulatory authorities in the Russian Federation. Nasopharyngeal lavage was collected and evaluated within 24 hours of hospitalization, using a rapid immunochromatographic RSV detection technique, QuickStripe™ RSV (Savyon Diagnositics Ltd, Ashdod, Israel). Two retests could be conducted within 24 A classification of children at "high-risk" for serious RSV infection was made based on a medical history of premature birth (#35 weeks of gestational age); chronic lung disease (CLD), including bronchopulmonary dysplasia (BPD); or congenital heart disease (CHD). The details of hospital stay and discharge were recorded from the hospital medical records using study-specific case report forms only for RSV-positive (RSV+) children. No hospitalization data were recorded for RSV-negative (RSV-) children. No subsequent visits were required for any enrolled child and no interventions were assessed in the study.
Data analysis
All children enrolled in the study formed the analysis population for primary and secondary analyses, irrespective of RSV diagnosis. The primary analysis, RSV prevalence, was determined by the number and proportion of RSV+ children (95% exact confidence interval [CI] for the proportion), calculated by dividing the total number of RSV+ children by the total number of children tested for RSV.
Seasonality was determined within the study period of September 2008 through April 2009. The number and proportion of RSV+ children enrolled was calculated at weekly intervals and across the entire study period. Calculations were performed for the total enrollment overall and for children from each of the three individual geographic areas.
Characteristics were evaluated using descriptive statistics. Means and standard deviations were calculated for continuous variables. For categorical variables, the number and percentage of enrollees in each category within an assessment were calculated.
Length of hospital stay, use and duration of oxygen supplementation, use of mechanical ventilation, use and duration of continuous positive airway pressure (CPAP), admission to an intensive care unit (ICU), duration of stay at ICU, and mortality were summarized descriptively. For continuous variables, comparisons of RSV+ children that were at "high risk" and "not at high risk" for serious RSV infection (based on medical history as described in Methods) were made using a one-way analysis of variance (ANOVA) with group as the only factor. For categorical variables, the number and percentage of children in each category within an assessment were calculated for non-missing data, and comparisons of RSV+ children that were at "high risk" and "not at high risk" for serious RSV infection were made using Fisher's exact test. P-values were based on two-tailed tests. Tests resulting in a P value # 0.05 were considered statistically significant.
Risk and protective factors were descriptively compared between RSV+ and RSV-children. No statistical tests were performed on these comparisons. Of 593 children aged #2 years assessed for inclusion in the study, 520 were enrolled. The primary reason for non inclusion was parental unwillingness to provide consent. The withdrawal of consent occurred for one enrolled child prior to RSV testing. The total data set for this study comprised the remaining 519 children. Table 1 summarizes the demographic characteristics of all children enrolled, of the RSV+ subset, and of highrisk RSV+ individuals by location. Children with RSV+ were predominantly full-term, white, males, of an appropriate weight for gestational age, and 7.5 months of age, on average, at hospitalization. These characteristics were similar to those of the total set; however, the mean age at hospitalization in the RSV-subset was 9.7 months.
Results
Enrollment
In physical examination conducted at enrollment, vital signs (mean ± SD) were similar among the subsets: respiratory rate (40.9 ± 10.60 breaths⋅min -1 ) and heart rate (130.5 ± 12.88 b⋅min -1 ), oxygen saturation (96.0 ± 2.60%), temperature (37.0 ± 0.58°C), length (68.9 ± 10.09 cm) and body weight (8.5 ± 2.69 kg). 
Prevalence and seasonality of rsV
Morbidity and mortality
Among high-risk RSV+ children, the length of hospital stay ranged from 4-13 days vs 1-37 days among RSV+ children without high-risk conditions. More of the RSV+ children at high risk for serious RSV infection required oxygen supplementation than the other RSV+ children not at high risk (28% v 10%, P = 0.04). The maximum duration of oxygen supplementation was 7-10 days, irrespective of risk category. No mechanical ventilation, CPAP, or surgeries were required and there were no deaths.
risk and protective factors
Physiological risk factors have been described above. In addition to those already presented, family and social history factors were identified and are described in Table 2 . In the RSV+ subset at high risk for serious RSV infection, 14 children were born premature, two had a history of CHD, and two had a history of CLD/BPD. Two criteria were identified for one high-risk child with RSV+ who was born premature and had a history of BPD. Medical histories revealed one or more hospitalizations in the high-risk RSV+ subset (50%), compared with the RSV+ (25%) and RSV-(37%) subsets not at high risk. Similarly, in the high-risk RSV+ subset, 50% of the children had been admitted to an ICU at birth, compared with 4% in the RSV+ and 7% in the RSV-subsets not at high risk.
Discussion
The prevalence of RSV during the 2008-2009 season in the Russian Federation was consistent with that expected in a northern temperate zone. The peak of RSV activity occurred in March-April. Both the prevalence of RSV and the peak of RSV activity were similar in the three participating cities. An abnormally warm autumn and a late winter cold-weather onset were recorded in temperate regions of the Russian Federation during the 2008-2009 season. 26 This unexpected factor serves as a reminder that a single season may not be representative of the RSV season from year to year. (5) 13 (7) 5 (29) Considering the variability reported in published epidemiological studies, the late arrival of the RSV peak was not exceptional. Russia may have an epidemiology similar to that of Finland, Sweden, and Norway, where later seasons are a regular occurrence not associated with the weather, and RSV peaks in March-April. 18 Such variability is not only found in far north or northeastern European countries. In Croatia, RSV seasons have two-year cycles, with seasons occurring from October to April one year and from December to June the next year, and with corresponding peaks in December-January and March-May. 13, 21 In Ireland, RSV onset occurs in November and year-to-year, the RSV peaks vary in occurrence from December through February. 27 The RSV peak reported in Germany appears to be dependent upon the timing of RSV season onset, such that when onset is in December, peak activity has been reported in March. 22, 23 In Italy, RSV onset occurs in December, peaks in March, and offsets in April. 28, 29 In Turkey, RSV peaks in March, with onset in September and offset in May. 24 The prospective design of this study contributed to the generalizability of results. All children with LRTI hospitalized in the participating centers were regarded as potential candidates for the study; therefore, the study was designed to represent the general population and to evaluate the prevalence of risk factors for RSV+ LRTI. By design, demographic data, risk and protective factors, and other descriptive information of the study population were collected without bias before the RSV test was administered.
Demographic characteristics and risk factors for severe RSV infection identified in the Russian Federation were consistent with those in other developed countries where children most at risk are those born premature, with chronic lung disease, or with congenital heart disease. 19, 30 Risk factors for hospitalization, such as sex (male); low birth weight (,10th percentile); exposure to school-age children in the home; daycare attendance; failure to breast feed beyond two months; cigarette smoke exposure; crowded living conditions; chronologic age ,six months at the time of RSV exposure; and being underweight at birth, 31,32 were also factors in the children with RSV+ LRTI. It is important to keep in mind that in previous studies, children born shortly before or during the RSV season were significantly more likely to be hospitalized for RSV+ LRTI than children born during other periods of the year.
31,32 These implications are key in that children who are at the highest risk of infection and complications leading to hospitalization are those most in need of prophylaxis.
Limitations of the study that may have influenced the results include the sensitivity of the rapid immunochromatographic RSV detection method (70%-90%), leaving a potential 10%-30% margin of error in identifying RSV infections. Enrollments in St Petersburg and Tomsk were relatively low and each city had only one participating site, therefore the prevalence of RSV in those cities may not have been adequately captured. Additional studies would be needed to provide a more precise definition of the RSV season than those provided by data collected during a single season. Although it can be argued that such factors can be generalizable for all regions of the Russian Federation as a whole, the epidemiological data collected in this study remain both valuable and important as they are consistent with what has been documented globally and in Europe concerning RSV.
This study confirms that RSV is widespread among populations in three major temperate regions of the Russian Federation and is a significant cause of LRTI leading to the hospitalization of young children. During one RSV "season", September 2008 through April 2009, enough data were obtained to evaluate the burden and need for RSV prophylaxis in high-risk infants. Inclusion criteria ensured homogeneity of the population and objective, evidence-based medical diagnosis procedures were adequate to support a conclusion regarding the disease prevalence and seasonality. All of these factors contribute to the generalizability of the results for the purposes intended; specifically, the preparation of health facilities to meet the burden of care and the effective timing of RSV prophylaxis with palivizumab. Although the period of peak activity occurred in March-April, later than previously reported in temperate regions of the northern hemisphere (December-January), it was not exceptional or inconsistent with ranges reported overall. The seasonality of RSV was similar with respect to onset and peak RSV activity between each of the three participating cities (regions). The demographics and risk factors identified among children hospitalized with RSV were similar to those described outside of the Russian Federation. These data support the consideration of an effective time period for RSV control measures, including RSV prophylaxis in children at high risk for serious RSV infection requiring hospitalization.
Conclusion
7
All randomized patients were included in the safety and efficacy analyses. Statistical comparison of groups was performed using Fisher's exact test for categorical variables and Wilcoxon rank sum test for continuous variables. The proportion of children with RSV hospitalization at 150 days was estimated by the Kaplan-Meier method as an alternative analysis of the primary endpoint. Logistic regression was also performed on the primary endpoint to evaluate predefined covariates (gender, age, weight, BPD vs premature without BPD). For comparison of hospital days between groups, the data were transformed and reported as days per 100 children.
RESULTS
Characteristics of the Randomized Populations at Entry
A total of 1502 children were randomized-500 to the placebo group and 1002 to the palivizumab group. The United States, the United Kingdom, and Canada randomized 1277 (85%), 123 (8%), and 102 (7%) children, respectively. The mean number of children randomized at a participating institution was 11 (range, 2-25); 8 centers randomized fewer than 5 patients and 27 centers randomized 15 or more. Demographic parameters and RSV risk factors were similar in the two groups (Table 1) ; slightly more children in the palivizumab group had at least one smoker in the household.
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Compliance and Serum Palivizumab Concentrations
A total of 1486 (99%) children completed the protocol follow-up (99% placebo, 99% palivizumab). Reasons for noncompletion included death (n ϭ 7), withdrawal of consent (n ϭ 4), or loss to follow-up (n ϭ 5) before day 150 and before any RSV hospitalization. Overall, 94% of the placebo group and 92% of the palivizumab group received all five injections and more than 95% of both groups received at least four injections. The proportion of children who received none, one, two, and three injections was similar in each group. Mean (standard error) trough serum concentrations 30 days after injections one, two, three, and four of 15 mg/kg palivizumab were 37 (1.2) g/mL, 57 (2.4) g/mL, 68 (2.9) g/mL, and 72 (1.7) g/mL, respectively.
Incidence of RSV Hospitalization
Monthly prophylaxis with palivizumab was associated with a 55% (95% CI ϭ 38%, 72%) reduction in hospitalization as a result of RSV (P ϭ .00004). This result was robust, with similar results obtained in alternative and sensitivity analyses (Table 2) . Significant reductions were observed in both children with BPD (39% reduction, P ϭ .038) and premature children without BPD (78% reduction, P Ͻ .001).
Significant reduction in RSV hospitalizations were seen in infants Ͼ5 kg (51%, P ϭ .014) and Յ5 kg (57%, P ϭ .001) and in infants Ͻ32 weeks' gestational age (47%, P ϭ .003) and 32 through 35 weeks' gestational age (80%, P ϭ .002). After adjusting for gender, entry age, entry weight, and BPD in a logistic regression model, treatment with palivizumab remained highly statistically significant (P Ͻ .001). When included in the logistic regression analysis, gestational age was not a significant predictor of RSV hospitalization and the palivizumab effect remained statistically significant (P Ͻ .001). 
Secondary Efficacy Endpoints
Children randomized to palivizumab had significantly fewer total days (per 100 children) of RSV hospitalization (62.6 placebo days vs 36.4 palivizumab days, P Ͻ .001), days with increased oxygen (50.6 days vs 30.3 days, P Ͻ .001), and days with an LRI score of 3 or greater (47.4 days vs 29.6 days, P Ͻ .001). Overall, the incidence of intensive care unit (ICU) admissions and mechanical ventilation for RSV was low. A few children with complex underlying disease and consequently prolonged hospitalization greatly influenced the distribution of days of Abbreviations: RSV, respiratory syncytial virus; CI, confidence interval; BPD, bronchopulmonary dysplasia. * Fisher's exact test. † Kaplan-Meier estimate of the proportion at 150 days. Deaths before RSV hospitalization, withdrawals, and lost events were treated as censored. ‡ The number of children who stopped follow-up before day 150 and had no endpoint through the last follow-up visit and would have been hospitalized if the proportion hospitalized was equal to that of the other treatment group added to observed incidence of RSV hospitalization. For placebo 5 children ϫ 0.048 (RSV hospitalization rate in palivizumab group) ϭ 0.24 (0 added events); for palivizumab 11 children ϫ 0.106 (RSV hospitalization in placebo) ϭ 1.17 (1 added event). § Number of children with respiratory hospitalizations and evidence of infection (coryza, fever) who had no alternative etiology added to observed incidence of RSV hospitalization. Three no antigen respiratory hospitalizations (0.6%) in the placebo group and 6 (0.6%) in the palizivumab group.
ARTICLES 533 at Abbott Labs on December 18, 2007 www.pediatrics.org Downloaded from these parameters. Three percent of placebo patients and 1.3% of palivizumab recipients had RSV ICU admissions (P ϭ .026); total days were 12.7 and 13.3, respectively (P ϭ .023). The placebo and treated groups did not show significant differences in incidence of mechanical ventilation (0.2% vs 0.7%, P ϭ .280) or total days of mechanical ventilation (1.7 days vs 8.4 days, P ϭ .210).
Palivizumab recipients had significant reductions in the incidence (31% vs 24%, P ϭ .011) and total days per 100 children (242 days vs 191 days, P ϭ .005) of all hospitalizations and the incidence (22% vs 16% P ϭ .008) and total days per 100 children (180 days vs 124 days, P ϭ .004) of respiratory hospitalizations. These differences were attributable to the observed reduction of RSV hospitalizations, because no significant differences were observed in the incidence (14% vs 13%, P ϭ .470) or total days per 100 children (118 days vs 88 days, P ϭ .369) of respiratory hospitalizations unrelated to RSV. The proportion of children with at least one episode of otitis media was similar in both placebo and palivizumab recipients (40% vs 42%, P ϭ .505).
Safety and Immunogenicity
The number of children reporting adverse events judged by the blinded investigator to be related to the study drug was similar in the placebo (10%) and the palivizumab (11%) groups. No statistically significant differences were found in related events by body system (Table 3) . Discontinuation of injections for adverse events related to palivizumab was rare (0.3%).
Overall, 1.8% of the placebo group and 2.7% of the palivizumab group reported adverse events related to the injection site. These included erythema (1.2% vs 1.4%), pain (0.0% vs 0.6%), induration/swelling (0.2% vs 0.6%), and bruising (0.4% vs 0.3%). These events were generally mild and of short duration; none was serious. The proportion of children who reported fever (3.0% vs 2.8%) or rash (0.2% vs 0.9%) judged related to the study drug was similar in the placebo and palivizumab groups (Table 3) . Hepatic transaminases were measured at baseline and before the fourth injection in all patients. Compared with the placebo group (1.6%), mild or moderate elevations of aspartate aminotransferase occurred in a slightly higher percentage (3.6%) of palivizumab recipients, however, a corresponding pattern in alanine aminotransferase elevation was not seen (2.0% and 2.3%, respectively). Hepatic adverse events that were judged by the blinded investigator and reported as related to the study drug were comparable in the two groups (Table 3) . Measured elevations of creatinine or blood urea nitrogen and renal adverse events were infrequent and occurred at a similar rate in both groups.
Five (1.0%) children in the placebo group and 4 (0.4%) in the palivizumab group died during the trial; no death was judged related to palivizumab. Two children in the palivizumab group and none in the placebo group died during hospitalization for RSV; 1 following surgery for tympanostomy tubes after recovery from RSV, another child with BPD had complications including liquid ventilation and bronchopneumonia. Three placebo (0.6%) and 7 palivizumab (0.7%) had RSV hospitalizations of 14 days or greater. Evaluation of their medical history and course of RSV did not reveal evidence of unanticipated severity of disease or risk factors other than severe BPD.
Anti-palivizumab binding was measured at intervals throughout the study. Titers greater than 1:40 were found in 2.8% of the placebo group and 1.2% of the palivizumab group. These were generally single elevations and were not associated with a pattern of adverse events or low palivizumab concentrations.
DISCUSSION
This study provides the first demonstration of the effectiveness of a monoclonal antibody in an infectious disease in humans. Monthly intramuscular injections of 15 mg/kg of palivizumab reduced the incidence of hospitalization because of a RSV infection compared with placebo by 55% (95% CI ϭ 38%, 72%), which compares favorably to a 41% (95% CI ϭ 10%, 72%) reduction previously reported with RSV-IGIV. 4 Although the PREVENT trial 4 established the effectiveness of antibody (RSV-IGIV), the study was not large enough to assess significant differences in subsets of the population studied. For example, efficacy was not statistically significant in premature infants without BPD nor in children Ͻ5 kg at entry (although the trends in these subsets were the same as for the entire study population). The sample size in the IMpact-RSV study was large enough to allow exploration of these issues. Significant reductions in RSV hospitalizations were seen in both premature infants without BPD and those with BPD who received palivizumab and in children by weight and gestational age. The study has established that palivizumab protects against serious RSV disease regardless of BPD status, gestational age, or weight of a high-risk child receiving prophylaxis. Abbreviations: AST, aspartate aminotransferase; URI, upper respiratory tract illness; ALT, alanine aminotransferase. * Reported events in at least 3 children in the palivizumab group are provided along with the corresponding incidence in the placebo group. These represent adverse events reported by the investigator and include those identified by protocol mandated testing and other clinically indicated evaluations. † Refers primarily to elevations of both AST and ALT. 
